Glucose-insulin-potassium (GIK) treatment for acute myocardial infarction has the potential to reduce mortality by 28% to 48%, according to prior meta-analysis data discussed in this editorial.
Does glucose-insulin-potassium (GIK) in combination with thrombolysis reduce mortality in patients with acute myocardial infarction?
This editorial highlights a prospective trial by the ECLA Collaborative Group that shows dramatic results for GIK therapy combined with thrombolysis in acute myocardial infarction.
landmark study is reported in this issue of Circulation, 1 continuing the rediscovery of glucose-insulin-potassium (GIK) treatment of acute myocardial infarction (AMI) that began in this journal last year with a meta-analysis and editorial. 2,3 That meta-analysis considered all prior randomized trials of GIK for AMI (these were all done in the prethrombolytic era) and concluded that GIK had the potential to reduce AMI mortality by 28% to 48% depending on dosage and timing of therapy initiation relative to symptom onset. An accompanying editorial called for a modern large-scale trial of GIK in combination with thrombolysis for AMI. Such a prospective trial is now reported by the ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group, and the results are dramatic.
Carl S. Apstein (Tue,) conducted a editorial in Acute Myocardial Infarction. Glucose-insulin-potassium (GIK) was evaluated on AMI mortality. Glucose-insulin-potassium (GIK) treatment for acute myocardial infarction has the potential to reduce mortality by 28% to 48%, according to prior meta-analysis data discussed in this editorial.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: